688796 百奥赛图
已收盘 02-10 15:00:00
资讯
新帖
简况
每周股票复盘:百奥赛图(688796)补选刘弘康为非执行董事
证券之星 · 02-08 03:15
每周股票复盘:百奥赛图(688796)补选刘弘康为非执行董事
百奥赛图(688796)披露补选非执行董事候选人公告,2月4日股价下跌1.94%
证券之星 · 02-04
百奥赛图(688796)披露补选非执行董事候选人公告,2月4日股价下跌1.94%
港股异动 | 百奥赛图-B(02315)再涨超5% 主业景气带动收入高增 机构看好公司长期增长潜力
智通财经 · 02-04
港股异动 | 百奥赛图-B(02315)再涨超5% 主业景气带动收入高增 机构看好公司长期增长潜力
港股异动 | 百奥赛图-B(02315)再涨超10% 全年纯利预增最多4.4倍 公司已达成多项重磅对外授权
智通财经 · 02-03
港股异动 | 百奥赛图-B(02315)再涨超10% 全年纯利预增最多4.4倍 公司已达成多项重磅对外授权
港股百奥赛图盘中涨超24%!预计全年营收增长约40%,纯利增长约400%
老虎资讯综合 · 01-30
港股百奥赛图盘中涨超24%!预计全年营收增长约40%,纯利增长约400%
港股异动 | 百奥赛图-B(02315)盈喜后涨近13% 预计全年营收增长约40% 纯利增长约400%
智通财经 · 01-30
港股异动 | 百奥赛图-B(02315)盈喜后涨近13% 预计全年营收增长约40% 纯利增长约400%
百奥赛图(688796)披露2025年年度业绩预盈公告,1月29日股价下跌3.37%
证券之星 · 01-29
百奥赛图(688796)披露2025年年度业绩预盈公告,1月29日股价下跌3.37%
百奥赛图-B(02315)发布2025年度业绩预告,预期归母净利润1.62亿元至1.82亿元 同比增加384.26%到443.88%
智通财经 · 01-29
百奥赛图-B(02315)发布2025年度业绩预告,预期归母净利润1.62亿元至1.82亿元 同比增加384.26%到443.88%
百奥赛图:2025年净利同比预增384%-444%
每日经济新闻 · 01-29
百奥赛图:2025年净利同比预增384%-444%
百奥赛图-B(02315)拟使用闲置自有资金进行现金管理
智通财经 · 01-28
百奥赛图-B(02315)拟使用闲置自有资金进行现金管理
百奥赛图(688796)披露关于补选第二届董事会非执行董事的议案,1月27日股价上涨3.14%
证券之星 · 01-27
百奥赛图(688796)披露关于补选第二届董事会非执行董事的议案,1月27日股价上涨3.14%
百奥赛图-B(02315)建议委任刘弘康为非执行董事
智通财经 · 01-27
百奥赛图-B(02315)建议委任刘弘康为非执行董事
国泰海通证券:首予百奥赛图-B(02315)“增持”评级 “抗体货架”重构新药研发生态
智通财经 · 01-26
国泰海通证券:首予百奥赛图-B(02315)“增持”评级 “抗体货架”重构新药研发生态
港股异动 | 百奥赛图-B(02315)再涨近7% 公司已完成AI驱动抗体药物研发平台的本地化部署
智通财经 · 01-21
港股异动 | 百奥赛图-B(02315)再涨近7% 公司已完成AI驱动抗体药物研发平台的本地化部署
百奥赛图(688796)新增【AI智能体】概念
证券之星 · 01-15
百奥赛图(688796)新增【AI智能体】概念
百奥赛图-B盘中涨超12% 公司已完成AI驱动抗体药物研发平台的本地化部署
新浪港股 · 01-14
百奥赛图-B盘中涨超12% 公司已完成AI驱动抗体药物研发平台的本地化部署
百奥赛图-B(02315.HK)一度涨超12%
每日经济新闻 · 01-14
百奥赛图-B(02315.HK)一度涨超12%
百奥赛图-B盘中涨超11%再创新高 公司与育世博达成进一步合作
金融界 · 01-13
百奥赛图-B盘中涨超11%再创新高 公司与育世博达成进一步合作
百奥赛图-B(02315)通过基于选择权的评估框架与育世博达成进一步合作共同推进同类首创双特异性抗体双药物偶联物项目
智通财经 · 01-12
百奥赛图-B(02315)通过基于选择权的评估框架与育世博达成进一步合作共同推进同类首创双特异性抗体双药物偶联物项目
港股异动 | 百奥赛图-B(02315)盘中涨近10% 股价刷新上市新高 与育世博达成进一步合作
智通财经 · 01-12
港股异动 | 百奥赛图-B(02315)盘中涨近10% 股价刷新上市新高 与育世博达成进一步合作
加载更多
公司概况
公司名称:
百奥赛图(北京)医药科技股份有限公司
所属行业:
研究和试验发展
上市日期:
2025-12-10
主营业务:
百奥赛图(北京)医药科技股份有限公司是一家主要从事药物开发业务及临床前研究的公司。该公司通过五个分部开展业务。基因编辑服务分部提供基于动物和细胞的定制化基因编辑服务。临床前药理药效评估分部提供用于药物疗效和毒性评估的临床前药理学服务。模式动物销售分部培育和销售外用和内用模式动物。抗体开发分部利用抗体发现平台识别有可能成为候选药物的抗体。创新药开发分部研发创新药,专注肿瘤学和自身免疫性疾病治疗。
发行价格:
26.68
{"stockData":{"symbol":"688796","market":"SH","secType":"STK","nameCN":"百奥赛图","latestPrice":75.15,"timestamp":1770706800000,"preClose":71.65,"halted":0,"volume":2820409,"delay":0,"changeRate":0.0488,"floatShares":35887600,"shares":447000000,"eps":0,"marketStatus":"已收盘","change":3.5,"latestTime":"02-10 15:00:00","open":71.64,"high":76.27,"low":71.64,"amount":211000000,"amplitude":0.0646,"askPrice":75.15,"askSize":431,"bidPrice":75.1,"bidSize":53,"shortable":0,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770773400000},"marketStatusCode":5,"adr":0,"adjPreClose":71.65,"symbolType":"stock_kcb","openAndCloseTimeList":[[1770687000000,1770694200000],[1770699600000,1770706800000]],"highLimit":78.82,"lowLimit":64.49,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":446898420,"isCdr":false,"pbRate":34.42,"roa":"--","roe":"12.61%","epsLYR":0.08,"committee":-0.1274,"marketValue":33584000000,"turnoverRate":0.0786,"status":0,"afterMarket":{"amount":0,"volume":0,"close":75.15,"buyVolume":0,"sellVolume":0,"time":1770708837558,"indexStatus":"已收盘 02-10 15:30:00","preClose":71.65},"hkstockBrief":{"symbol":"02315","market":"HK","secType":"STK","nameCN":"百奥赛图-B","latestPrice":49.8,"timestamp":1770710952728,"preClose":49.02,"halted":0,"volume":1483500,"delay":0,"premium":"-41.40"},"floatMarketCap":2697000000},"requestUrl":"/m/hq/s/688796","defaultTab":"news","newsList":[{"id":"2609264055","title":"每周股票复盘:百奥赛图(688796)补选刘弘康为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2609264055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609264055?lang=zh_cn&edition=full","pubTime":"2026-02-08 03:15","pubTimestamp":1770491712,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘,百奥赛图报收于70.96元,较上周的72.59元下跌2.25%。股本股东变化:截至2026年1月31日,公司H股和A股已发行股份均无变动。百奥赛图(北京)医药科技股份有限公司因非执行董事魏义良辞职,拟补选刘弘康为第二届董事会非执行董事候选人,任期至本届董事会任期届满。刘弘康的任职资格符合相关法律法规及公司章程规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800001177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688796"],"gpt_icon":0},{"id":"2608985203","title":"百奥赛图(688796)披露补选非执行董事候选人公告,2月4日股价下跌1.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608985203","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608985203?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:30","pubTimestamp":1770215437,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘,百奥赛图报收于70.25元,较前一交易日下跌1.94%,最新总市值为313.95亿元。该股当日开盘71.64元,最高72.5元,最低68.64元,成交额达1.49亿元,换手率为5.91%。近日,百奥赛图(北京)医药科技股份有限公司披露《2026年第一次临时股东会会议资料》。公告显示,因公司非执行董事魏义良辞职,董事会拟补选刘弘康为第二届董事会非执行董事候选人,任期至本届董事会任期届满。刘弘康的任职资格符合相关法律法规及公司章程规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688796"],"gpt_icon":0},{"id":"2608582353","title":"港股异动 | 百奥赛图-B(02315)再涨超5% 主业景气带动收入高增 机构看好公司长期增长潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2608582353","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608582353?lang=zh_cn&edition=full","pubTime":"2026-02-04 15:28","pubTimestamp":1770190106,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B再涨超5%,截至发稿,涨5.41%,报47.96港元,成交额6986.85万港元。国联民生证券认为,创新动物模型及临床前CRO业务高景气带动收入高增。该行指出,2025年以来,公司与多家国内外头部药企达成对外授权,并有多条管线获得IND批准,随着授权管线的推进,公司有望获得里程碑付款等收入,进一步打开增长天花板。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","VT","02315","BK4585","688796","BK1161","BK4588","BK0216"],"gpt_icon":0},{"id":"2608481958","title":"港股异动 | 百奥赛图-B(02315)再涨超10% 全年纯利预增最多4.4倍 公司已达成多项重磅对外授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2608481958","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608481958?lang=zh_cn&edition=full","pubTime":"2026-02-03 11:02","pubTimestamp":1770087766,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B再涨超10%,截至发稿,涨8.58%,报45.56港元,成交额6619.52万港元。消息面上,百奥赛图近期发布2025年度业绩预告,预期归母净利润1.62亿元至1.82亿元,同比增加384.26%到443.88%。公告称,受益于海外市场的持续拓展,叠加国内生物医药行业的复苏回暖,公司营业收入实现高速增长。高壁垒的技术优势保障业务毛利维持高位,精益化管理举措进一步推动运营效率提升,公司盈利水平得以快速提高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400891.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4588","02315","BK0216","VT","BK4585","688796"],"gpt_icon":0},{"id":"1124857080","title":"港股百奥赛图盘中涨超24%!预计全年营收增长约40%,纯利增长约400%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124857080","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124857080?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:57","pubTimestamp":1769738220,"startTime":"0","endTime":"0","summary":"1月30日,$百奥赛图-B$盈喜后涨超24%,预计全年营收增长约40%,纯利增长约400%。消息面上,$百奥赛图$发布2025年度业绩预告,预计全年实现营收约13.69亿元-13.89亿元,较上年同期增加3.89亿元至4.08亿元,同比增幅为39.61%到41.65%;预计实现归母净利润约为1.62亿元-1.82亿元,较上年同期增加1.29亿元至1.49亿元,同比大幅增长384.26%至443.88%。","market":"hk","thumbnail":"https://static.tigerbbs.com/9bedac14febdf709f4cca99ceb4b91b1","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/9bedac14febdf709f4cca99ceb4b91b1"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1a25853d795dfd507082cf4888ca5511","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VT","02315","BK4585","688796","BK4588","BK0216"],"gpt_icon":0},{"id":"2607906696","title":"港股异动 | 百奥赛图-B(02315)盈喜后涨近13% 预计全年营收增长约40% 纯利增长约400%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607906696","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607906696?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:43","pubTimestamp":1769737415,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B盈喜后涨近13%,截至发稿,涨8.82%,报47.88港元,成交额2771.5万港元。消息面上,百奥赛图发布2025年度业绩预告,预计全年实现营收约13.69亿元-13.89亿元,较上年同期增加3.89亿元至4.08亿元,同比增幅为39.61%到41.65%;预计实现归母净利润约为1.62亿元-1.82亿元,较上年同期增加1.29亿元至1.49亿元,同比大幅增长384.26%至443.88%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"1a25853d795dfd507082cf4888ca5511","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688796","02315","VT"],"gpt_icon":0},{"id":"2607036271","title":"百奥赛图(688796)披露2025年年度业绩预盈公告,1月29日股价下跌3.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607036271","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607036271?lang=zh_cn&edition=full","pubTime":"2026-01-29 23:00","pubTimestamp":1769698847,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘,百奥赛图报收于66.58元,较前一交易日下跌3.37%,最新总市值为297.54亿元。该股当日开盘68.9元,最高69.69元,最低66.35元,成交额达1.07亿元,换手率为4.41%。近日,百奥赛图(北京)医药科技股份有限公司发布2025年年度业绩预盈公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900044105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688796"],"gpt_icon":0},{"id":"2607704829","title":"百奥赛图-B(02315)发布2025年度业绩预告,预期归母净利润1.62亿元至1.82亿元 同比增加384.26%到443.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607704829","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607704829?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:34","pubTimestamp":1769675699,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百奥赛图-B 发布2025年度业绩预告,经公司财务部门初步测算,预计本集团2025年年度实现营业收入人民币13.69亿元至人民币13.89亿元,与上年同期相比,将增加人民币3.88亿元至人民币4.08亿元,同比增加39.61%至41.65%。预计本集团2025年年度实现归属于母公司所有者的净利润人民币1.62亿元至人民币1.82亿元,与上年同期相比,将增加人民币1.29亿元到人民币1.49亿元,同比增加384.26%到443.88%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399134.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02315","688796"],"gpt_icon":0},{"id":"2607070459","title":"百奥赛图:2025年净利同比预增384%-444%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607070459","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607070459?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:30","pubTimestamp":1769675433,"startTime":"0","endTime":"0","summary":"每经AI快讯,1月29日,百奥赛图(688796.SH)公告称,预计2025年归属于上市公司股东的净利润为1.62亿元至1.82亿元,同比增长384.26%至443.88%。受益于海外市场的持续拓展,叠加国内生物医药行业的复苏回暖,公司营业收入实现高速增长。高壁垒的技术优势保障业务毛利维持高位,精益化管理举措进一步推动运营效率提升,公司盈利水平得以快速提高。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601293635257272.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601293635257272.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0216","688796"],"gpt_icon":0},{"id":"2606519777","title":"百奥赛图-B(02315)拟使用闲置自有资金进行现金管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2606519777","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606519777?lang=zh_cn&edition=full","pubTime":"2026-01-28 08:07","pubTimestamp":1769558840,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百奥赛图-B(02315)发布公告,为提高公司自有资金使用效率,在确保不影响公司正常生产经营以及确保资金安全的前提下,公司拟合理利用部分闲置自有资金进行现金管理,可以提高自有资金使用效率,增加公司现金资产收益,为公司及股东获取更多投资回报。公司拟使用不超过人民币5亿元(含本数)的暂时闲置自有资金进行现金管理,在前述额度范围内,资金可以循环滚动使用。公司拟使用暂时闲置自有资金用于购买安全性高、流动性好、风险较低的银行及其他金融机构发行的理财产品进行委托理财。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02315","688796","BK0216","BK1161"],"gpt_icon":0},{"id":"2606878008","title":"百奥赛图(688796)披露关于补选第二届董事会非执行董事的议案,1月27日股价上涨3.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606878008","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606878008?lang=zh_cn&edition=full","pubTime":"2026-01-27 22:27","pubTimestamp":1769524033,"startTime":"0","endTime":"0","summary":"截至2026年1月27日收盘,百奥赛图报收于70.86元,较前一交易日上涨3.14%,最新总市值为316.67亿元。该股当日开盘67.67元,最高71.5元,最低67.55元,成交额达1.96亿元,换手率为7.83%。近日,百奥赛图(北京)医药科技股份有限公司披露《关于补选公司第二届董事会非执行董事的议案》。该议案已获公司第二届董事会第十五次会议审议通过,拟提交将于2026年2月12日召开的2026年第一次临时股东大会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700041962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688796"],"gpt_icon":0},{"id":"2606887780","title":"百奥赛图-B(02315)建议委任刘弘康为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2606887780","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606887780?lang=zh_cn&edition=full","pubTime":"2026-01-27 22:08","pubTimestamp":1769522909,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百奥赛图-B(02315)发布公告,经董事会提名委员会提名及董事会审议,董事会于2026年1月27日举行的董事会会议上建议委任刘弘康先生为非执行董事。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398230.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","02315","BK1161","688796"],"gpt_icon":0},{"id":"2606262504","title":"国泰海通证券:首予百奥赛图-B(02315)“增持”评级 “抗体货架”重构新药研发生态","url":"https://stock-news.laohu8.com/highlight/detail?id=2606262504","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606262504?lang=zh_cn&edition=full","pubTime":"2026-01-26 09:09","pubTimestamp":1769389785,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,国泰海通证券发布研报称,首次覆盖,给予百奥赛图-B“增持”评级。公司作为全球领先的创新药临床前CRO及生物技术公司,技术壁垒深厚,临床前产品与服务收入稳定增长,“千鼠万抗”计划进入兑现期。“千鼠万抗”计划进入兑现期,抗体开发与授权业务形成强力增长引擎百奥赛图以“抗体货架”为核心的创新模式,打破传统抗体开发的效率瓶颈,成为公司差异化竞争的核心引擎。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","02315","02611","688796"],"gpt_icon":0},{"id":"2605129183","title":"港股异动 | 百奥赛图-B(02315)再涨近7% 公司已完成AI驱动抗体药物研发平台的本地化部署","url":"https://stock-news.laohu8.com/highlight/detail?id=2605129183","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605129183?lang=zh_cn&edition=full","pubTime":"2026-01-21 10:27","pubTimestamp":1768962437,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B(02315)再涨近7%,截至发稿,涨5.08%,报39.72港元,成交额2832.35万港元。消息面上,百奥赛图近日在互动平台表示,公司已完成AI驱动抗体药物研发平台的本地化部署,并实现其与公司核心业务千鼠万抗计划的全面协同。通过AI的本地化部署,公司正在建设抗体药物研发ai智能体。随着千鼠万抗计划与AI系统深度整合的持续推进,公司将为全球药企提供更加高效的研发工具和更为丰富的抗体分子库,帮助药企伙伴提高临床前PCC分子的研发效率,这也将推动抗体发现业务迈入全新发展阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1395442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02800","BK0216","688796","BK1161","BK1610","02315"],"gpt_icon":0},{"id":"2603560789","title":"百奥赛图(688796)新增【AI智能体】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2603560789","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603560789?lang=zh_cn&edition=full","pubTime":"2026-01-15 20:30","pubTimestamp":1768480219,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,1月15日百奥赛图新增概念。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500037981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","159819","688796"],"gpt_icon":0},{"id":"2603665720","title":"百奥赛图-B盘中涨超12% 公司已完成AI驱动抗体药物研发平台的本地化部署","url":"https://stock-news.laohu8.com/highlight/detail?id=2603665720","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603665720?lang=zh_cn&edition=full","pubTime":"2026-01-14 10:08","pubTimestamp":1768356480,"startTime":"0","endTime":"0","summary":" 百奥赛图-B盘中涨超12%,近三日累涨约30%。截至发稿,股价上涨7.58%,报46港元,成交额5387.96万港元。 1月13日,百奥赛图在互动平台表示,公司已完成AI驱动抗体药物研发平台的本地化部署,并实现其与公司核心业务千鼠万抗计划的全面协同。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-01-14/doc-inhhfrsv5260509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688796","02315","BK0216","BK1161"],"gpt_icon":0},{"id":"2603650957","title":"百奥赛图-B(02315.HK)一度涨超12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603650957","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603650957?lang=zh_cn&edition=full","pubTime":"2026-01-14 10:03","pubTimestamp":1768356223,"startTime":"0","endTime":"0","summary":"每经AI快讯,百奥赛图-B(02315.HK)一度涨超12%,近三日累涨约30%。截至发稿,百奥赛图-B涨6.74%,报45.64港元,成交额2818万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601143618563076.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601143618563076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02315","BK0216","BK1161","688796"],"gpt_icon":0},{"id":"2603571312","title":"百奥赛图-B盘中涨超11%再创新高 公司与育世博达成进一步合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2603571312","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603571312?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:34","pubTimestamp":1768275273,"startTime":"0","endTime":"0","summary":"百奥赛图-B盘中涨超11%,高见44港元,再创历史新高。据悉,该协议将授予育世博一项选择权以获得百奥赛图两项BsADC项目的全球独家许可。百奥赛图将有权获得选择权首付款;在育世博行使相关选择权后,百奥赛图还可获得包括选择权行使费、开发和监管里程碑付款、商业化里程碑付款以及销售分成在内的后续款项。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/01/13113455031362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","02315","BK0216","688796"],"gpt_icon":0},{"id":"2602511720","title":"百奥赛图-B(02315)通过基于选择权的评估框架与育世博达成进一步合作共同推进同类首创双特异性抗体双药物偶联物项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2602511720","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602511720?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:50","pubTimestamp":1768218604,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百奥赛图-B 发布公告,近日,公司与育世博股份有限公司(育世博)达成一项选择权与许可协议,旨在通过结构化的评估机制,对双特异性抗体药物偶联物项目开展系统性评估,从而进一步加速双特异性抗体双药物偶联物的开发进程。此前,双方的合作重点聚焦于对有成药潜力的双特异性抗体及双载荷抗体药物偶联物候选项目的评估与筛选。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","BK1161","688796","02315"],"gpt_icon":0},{"id":"2602561159","title":"港股异动 | 百奥赛图-B(02315)盘中涨近10% 股价刷新上市新高 与育世博达成进一步合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2602561159","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602561159?lang=zh_cn&edition=full","pubTime":"2026-01-12 09:43","pubTimestamp":1768182183,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B盘中涨近10%,高见39.46港元创上市新高。该协议将授予育世博一项选择权以获得百奥赛图两项BsADC项目的全球独家许可。百奥赛图将有权获得选择权首付款;在育世博行使相关选择权后,百奥赛图还可获得包括选择权行使费、开发和监管里程碑付款、商业化里程碑付款以及销售分成在内的后续款项。信达证券近日研报指出,整体来看,百奥赛图模式动物销售业务和临床前药理药效评价业务协同发展,目前正处于高速成长期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","688796","BK0216","02315"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770747089299,"stockEarnings":[{"period":"1week","weight":0.049},{"period":"1month","weight":0.2569},{"period":"3month","weight":1.8167},{"period":"ytd","weight":0.4287}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0019},{"period":"3month","weight":0.0321},{"period":"6month","weight":0.126},{"period":"1year","weight":0.2427},{"period":"ytd","weight":0.0402}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百奥赛图(北京)医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"28549人","perCapita":"1257股","listingDate":"2025-12-10","address":"北京市大兴区中关村科技园区大兴生物医药产业基地宝参南街12号院","registeredCapital":"44689万元","survey":" 百奥赛图(北京)医药科技股份有限公司是一家主要从事药物开发业务及临床前研究的公司。该公司通过五个分部开展业务。基因编辑服务分部提供基于动物和细胞的定制化基因编辑服务。临床前药理药效评估分部提供用于药物疗效和毒性评估的临床前药理学服务。模式动物销售分部培育和销售外用和内用模式动物。抗体开发分部利用抗体发现平台识别有可能成为候选药物的抗体。创新药开发分部研发创新药,专注肿瘤学和自身免疫性疾病治疗。","listedPrice":26.68},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百奥赛图(688796)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百奥赛图(688796)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百奥赛图,688796,百奥赛图股票,百奥赛图股票老虎,百奥赛图股票老虎国际,百奥赛图行情,百奥赛图股票行情,百奥赛图股价,百奥赛图股市,百奥赛图股票价格,百奥赛图股票交易,百奥赛图股票购买,百奥赛图股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百奥赛图(688796)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百奥赛图(688796)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}